Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Blanco (Barcelona, Spain), M. Marquina (Barcelona, Spain), O. Tura-Ceide (Barcelona, Spain), V. Peinado (Barcelona, Spain), J. Barberà (Barcelona, Spain). Survivin inhibition as a potential target for pulmonary arterial hypertension. 5055

Member's Comments

No comment yet.

Related content which might interest you: HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006 Targeting cell motility in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 531-544 Year: 2013 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 The pathophysiological role of novel pulmonary arterial hypertension gene SOX17 Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020 Year: 2021 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 Towards an understanding of pulmonary arterial hypertension (PAH): gene regulation patterns in pulmonary arterial resistance vessels of patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 CFTR involvement in the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Multi-omic profiling in pulmonary arterial hypertension Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension Year: 2020 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017